Eicosanoid-mediated increase in glucose and lactate output as well as decrease and redistribution of flow by complement-activated rat serum in perfused rat liver first published in:
During inflammatory diseases severe metabolic impairment of intermediary metabolism and hemodynamics occurs locally at the site of inflammation as well as systemically during severe septicaemia or endotoxinaemia. In the course of these processes the complement system can be activated via a specific pathway that is initiated by antigen . antibody complexes, or by an unspecific, so called alternate pathway, that constitutes an autocatalytic process [l] . The alternate activation can be enhanced by cell-wall particles from yeast (zymosan) or Gram-negative bacteria [ 11. The activation of the complement system in vivo causes the synthesis of a variety of very potent mediators of inflammation and leads to the formation of a lytical membrane-bound complex. Whereas most of the components of the activated complement system are very unstable in the serum or are inactivated almost immediately after their formation [l] , so that they can be active only near their site of formation, others seem to escape the rapid inactivation and can exert effects in remote organs [l] .
Several agents which can activate the complement system either via the classic or the alternate pathway, e. g. heat-aggreCorrespondence to G. Puschel, Institut fur Biochemie, GeorgAugust-Universitat Gottingen, Humboldtallee 23, W-3400 Gottingen, Federal Republic of Germany Abbreviations. BM 13505, 4-[2-(4-~hlorobenzenesulfonamide)-ethyl]-benzeneacetic acid; CGP 35949 B, N-{3-[3-(4-acetyl-3-hydroxy-2-propyl-phenoxy)-propoxy]-4-chlorine-6-methyl-phenyl} -1 H-tetrazole-5-carboxamide sodium salt; Me2S0, dimethylsulfoxide; LTC4, leukotriene C4; LTD4, leukotriene D4; NDGA, nordihydroguaiaretic acid; PGFz,, prostaglandin F2=; TXAz, thromboxane A2; TXBz, thromboxane BZ.
Enzymes. Glucose dehydrogenase (EC 1.1.1.47); lactate dehydrogenase (EC 1 .I .I .27); glutamate pyruvate transaminase (EC 2.6.1.2) .
Note. Dedicated to Professor Karl Decker, Freiburg, on the occasion of his 65th birthday. gated immunoglobulins [2] , zymosan [3, 41 or endotoxins [5] , have been shown in rat liver perfused with a serum and cellfree medium, to increase glucose and lactate output and portal pressure directly without the intervention of the complement system. The purpose of this study was to examine in the perfused rat liver, whether rat serum in which the complement system had been activated with zymosan via the alternate pathway, could modulate liver metabolism and hemodynamics and which mediators were possibly involved. It was found that complement-activated rat serum increased glucose and lactate output and reduced, as well as redistributed, the flow. Metabolic and hemodynamic changes were accompanied by an overflow of thromboxane B2 (TXB2) and prostaglandin Fz, (PGF2,) into the hepatic vein and could be inhibited by indomethacin or the thromboxane antagonist, BM 13505.
MATERIALS AND METHODS

Chemicals
Dimethylsulfoxide (Me2SO), indomethacin, nordihydroguaiaretic acid (NDGA), zymosan and trypan blue were purchased from Sigma (Deisenhofen, FRG). Enzymes and coenzymes for the metabolite assays were bought from Boehringer (Mannheim, FRG), who also provided the thromboxane antagonist, BM 13505 as a gift. The Merck Glucose System was obtained from Merck (Darmstadt, FRG) . CGP 35949 B, was a gift from Ciba-Geigy (Basel, Switzerland). Radioimmunoassays for TXBz and PGFzE were bought from Amersham (Braunschweig, FRG). The carboxypeptidase inhibitor ~,~-mercapto-methyl-3-guanidinoethylthiopropanoic acid was from Calbiochem (Frankfurt, FRG). All other chemicals were from commercial sources and of analytical grade.
,4n imals
Male Wistar rats were bought from Winkelmann (Borchen, FRG) and kept on a 12-h day-night rhythm (light from 7 a.m. to 7 p. m.) for at least one week before the experiment with free access to water and a rat standard diet from Ssniff (Soest, FRG).
Preparation of rut .serum
Blood was collected from the inferior caval vein of anaesthetized rats that were to be sacrificed for organ sampling in other studies. After complete clotting, the blood was centrifuged at 5000 x g and the serum decanted. Serum from several rats was pooled and frozen in aliquots at -20°C for later use. It was stored for no longer than two weeks. The complement system was activated immediately before the perfusion experiment via the alternate pathway by incubation of the serum with zymosan (2 mg/ml, 1 h, 37°C). Zymosan, which previously had been shown to increase glucose output and perfusion pressure in perfused rat liver by itself [3, 4] , was then completely removed by centrifugation at 27000 x g for 30 min. The successful removal of zymosan by centrifugation was ascertained by infusion of the supernatant of zymosantreated Krebs-Henseleit buffer, which was inactive. Control serum was treated in exactly the same manner, but without zymosan. Control serum or activated serum were diluted in perfusion medium. 1 : 3 if not otherwise stated and infused at a rate of 2 ml/min, i.e. about 1/15 of the total perfusion flow.
Molecular muss determination of the active component of zymosan-treated rat serum
The bulk of protein was removed from rat serum which had been activated by incubation with zymosan, by precipitation with 10% (mass/vol.) polyethyleneglycol 6000 at pH 5.0. The supernatant (5 ml) of the precipitation was chromatographed on a Sephadex G75 column (2.5 cm diameter, 90 cm length) equilibrated with 25 mM Tris/HCl, pH 7.4. The flow rate was 18 ml/h, the fraction size was 2.25 ml. The column was calibrated with bovine serum albumin (68 kDa), chymotrypsinogen (25 kDa), myoglobin (17 kDa) and cytochrome c (12.5 kDa). Pools of 20 fractions each corresponding to roughly the molecular mass range 2 68 kDa, < 68 kDa-2 25 kDa, < 25 kDa-2 17 kDa, < 17 kDa-2 10 kDa, < 10 kDa, were lyophilized, redissolved in 4 ml water, filtered through a micropore filter (0.2 pm) and infused as described for activated serum.
Perjusion
Rats (160-190 g) were anaesthetized by intraperitoneal injection of pentobarbital (60 mg/kg). Livers were perfused in situ at a rate of about 30 ml/min via the portal vein, using a pressure constant, non-recirculating perfusion system described previously [6] . The perfusion medium was a KrebsHenseleit buffer pH 7.4,37"C, equilibrated with 0 2 / C 0 2 95: 5 (by vol.), containing 5 mM glucose, 2 mM lactate and 0.2 mM pyruvate, and in some experiments additionally 0.1 YO (mass/ vol.) bovine serum albumin, 0.1% (by vol.) Me2S0 and indomethacin, NDGA, BM 13505 or CGP 35949 B at the concentrations indicated.
Metabolite determination
Glucose was determined employing a commercial test kit based on the glucose dehydrogenase method (the Merck Glu-
Increase in glucose and lactate output, and reduction offlow after infusion of control and complement-activated rat serum in perfused rat liver. Rat livers were perfused in situ via the portal vein with a Krebs-Henseleit buffer, pH 7.4, containing 5 mM glucose, 2 mM lactate and 0.2 mM pyruvate. At the times indicated, control serum (CS) or complement-activated serum (AS) of the rat was infused at a rate so-that its final dilution was 1 :45. Perfusate was collected from the inferior caval vein every minute, the flow rate being measured as the volume of each fraction. Glucose and lactate output (kmol . min-' . g liver-') were calculated according to the formula: [posthepatic concentration (pmol . ml-I ) -prehepatic concentration (pmoI . mI-')] x flow (ml . min-' . g liver-'). Values are means SEM of the number of experiments given in parentheses cose System) [7] , lactate was measured in a combined optical test with lactic dehydrogenase and glutamic pyruvic transaminase in a basic glutamine buffer [8] . TXB2 and PGFz, were determined with radioimmunoassays from Amersham according to the instructions of the company.
RESULTS
Increase in glucose and lactate output us well as reduction and redistribution of'perfusion flow by complement-activated rat serum
Diluted (1 : 3) control and activated rat serum were infused in the isolated perfused rat liver at 1 / l 5 of the rate of perfusion flow, i.e. to a final dilution of 1 : 45 for 2 min, each with an interval of 8 min. The control serum increased glucose and lactate output and decreased the flow slightly (Fig. I A) . Rat serum, in which the complement system had been activated via the alternate pathway with zymosan, increased glucose and lactate output and decreased the flow strongly, the alterations being clearly larger than those observed with the control serum ( Fig. 1 A) . To exclude a sensitization of the liver as reason for the larger effects in the second infusion period, complementactivated serum was infused in the first period and control serum in the second period ( Fig. 1 B) . The increase in glucose and lactate output and the decrease in flow were the same with infusion of activated serum during the second and first period; however, the effects of the control serum were largely diminished with application during the second period. Activated serum no longer decreased the flow in the presence of the calcium antagonist nifedipine, which has been shown previously to prevent hemodynamic changes by sympatheticnerve stimulation, circulating noradrenaline and PGFza [9] ; yet, it still increased glucose and lactate output (not shown). This precludes hypoxia as a major cause for the increases in metabolite output by activated serum.
The flow reduction after infusion of activated serum was accompanied by a redistribution of the flow in the liver. Whereas under basal conditions the perfused liver was stained homogeneously with trypan blue infused to a final concentration of 0.2%, it was stained quite inhomogeneously during the action of activated serum (not shown). Some areas of the liver apparently were no longer perfused, whereas others remained perfused normally. After cessation of the infusion of activated serum, when the flow had returned to the basal level, the staining of the liver was homogeneous again.
Metabolic and hemodynamic alterations were dose dependent (Fig. 2) . A significant increase in glucose output and reduction of flow could still be observed at a final dilution of 1 : 750 of the activated serum.
Heating the serum to 57 "C for 30 min, which is a generally accepted method to inactivate the complement proteases and thus to prevent complement activation [lo, 111, prior to the treatment of the serum with zymosan, completely abolished the differences in action between zymosan-treated and control serum (Table 1 ). This shows that (a) the integrity of the complement system was necessary in order to generate the components that were responsible for the stronger metabolic and hemodynamic effects caused by zymosan-treated serum in comparison to control serum; (b) the zymosan particles, which by themselves interfere with liver metabolism and hemodynamics [3, 4] were completely removed from the serum after zymosan treatment. Heating of the serum to 57'C for 30 min after activation with zymosan, i.e. after formation of the active components of the complement system, did not significantly diminish the capacity of activated serum to increase glucose and lactate output and to decrease the flow. This shows that the active components of the activated serum were heat-resistent and therefore could only be low molecular mass proteins (< 20 kDa), polypeptides or oligopeptides, or small molecular mass substances. This interpretation was further substantiated by gel-chromatographic analysis of the activated serum. Zymosan-treated serum was subjected to a precipitation with 10% polyethyleneglycol; the supernatant was chromatographed on Sephadex G75. The components responsible for the increase in glucose and lactate output, and reduction of the flow, were found in pools corresponding to the molecular mass range of < 25 kDa-2 17 kDa and < 17 kDa-2 10 kDa. The latter showed a somewhat higher potency than the former (not shown).
The inhibitor of serum carboxypeptidase D,L-mercaptomethyl-3-guanidinoethylthiopropanoic acid [ 121, that was reported to prevent the degradation of the anaphylatoxins C3a and C5a in human serum (M. Oppermann, F. Liebmann, M. Schulze and 0. Gotze, unpublished results) and to enhance the effect of human anaphylatoxin C3a in perfused rat liver [13] , did not influence the extent of the metabolic and hemodynamic alterations (not shown).
Inhibition of the metabolic and hemodynamic effects of activated serum by eicosanoid-synthesis inhibitors and receptor antagonists
The increments of increases in glucose and lactate output and reduction of perfusion flow by activated serum over control serum were reduced by indomethacin (20 pM), an inhibitor of cyclooxygenase [14] and thus prostanoid synthesis, by more than 90% (Fig. 3) , whereas they were reduced by NDGA (20 pM), an inhibitor of lipoxygenase [15] and thus leukotriene synthesis by only about 50%. Likewise the thromboxane A2 (TXA,) receptor antagonist BM 13505 (20 pM) [16] , which blocked the metabolic and hemodynamic effects of the TXA2 analog U46619 in perfused rat liver and did not unspecifically interfere with the actions of leukotriene D4 (LTD4) or PGF2, (M. Iwai and K. Jungermann, unpublished results) , almost completely abolished the differences in the action between activated serum and control serum. However, the leukotriene C4 (LTC4)/LTD4 receptor antagonist CGP 35949 B (1 pM) [17], which completely blocked the metabolic and hemodynamic actions of LTC4 and LTD4 in perfused rat liver [18, 191 and also partially inhibited those of the TXA, agonist U46619 (G. P. Piischel, unpublished results), reduced the differences between activated and control serum in glucose output only by about 50% and left the lactate output and the flow reduction almost unaffected. Thus it appeared that the metabolic and hemodynamic effects of complement-activated rat serum were mediated primarily by TXA2.
Overflow of TXBz and PGF,, into the hepatic vein
Control serum contained 1.3 0.2 pM TXB, and 68 f 12 nM PGFza (SEM, n = 6). The levels of these pro- Table 1 . Increase in glucose and lactate output, and reduction in jlow after infusion of control and complement-activated rat serum heat treated before or ufter activation Rat livers were perfused as described in Fig. 1 stanoids, which were probably formed during the process of blood clotting, were identical in activated serum, i.e.
1.3 k 0.2 pM TXB2 and 72 2 19 nM PGF,, (SEM, n = 6).
Thus, during infusion of control or activated serum due to the 1 :45 dilution, the final concentrations of 28 nM TXB2 and 1.5 nM PGF2, were reached. TXB, is considered an inactive degradation product of the active TXA2. When infused to a final concentration of about 30 nM for 2 min, TXB, had no metabolic or hemodynamic effects (not shown). During a single path through the liver about 82% of 30 nM TXB, was degraded to products not detectible in the assay employed (Table 2 ). PGFza had previously been shown not to cause any metabolic or hemodynamic effects at nanomolar concen- trations [20 -221. When infused to a final concentration of 10 pM for 5 min, about 94% of PGF,, was degraded during a single passage through the liver to products that were not detectible with the assay used ( Table 2 ). These findings suggest that TXB2 and PGF,,, present in the control and activated serum, did not cause any significant alterations and that they were eliminated largely (TXB2) or almost completely (PGF2,) during their passage through the liver. 280 pmol TXBl was infused with the control serum/g liver during a 2-min period from 30 -32 min and about 38 pmol TXB2 was found in the effluent during a 10-min period from 30-40 rnin ( Table 2 ). The peak of the outflow was observed after 2 rnin at the end of the infusion period (Fig. 4A) . Less than 20% of the TXB2 infused with the control serum left the liver; a similar percentage of elimination was observed in Table 2 ). The peak of outflow was reached already after 1 min (Fig. 4A) . Similar results were obtained when activated serum was infused prior to control serum (Fig. 4B ). In the presence of the cyclooxygenase inhibitor indomethacin, after infusion of control or activated serum 27 f 6 pmol TXBz . g-l and 32 _+ 11 pmol TXB2 . g-was found in the effluent (Table 2) . Again less than 20% of the TXB2 infused with control or activated serum left the liver, which corresponded to the elimination of authentic TXB2. Thus, the higher amount of TXB2 found in the effluent after infusion of activated serum probably was due to a de novo formation of TXAz in response to activated serum. However, it cannot be excluded that a decrease of elimination of TXBz infused with activated serum was caused by the reduction and redistribution of flow and thus also contributed to the increased amount of TXB2 leaving the liver. 15 pmol PGFz, was infused with control and activated serum/g liver during a 2-min period from 30 -32 min. Since PGFza infused with the serum was degraded almost completely during its passage through the liver, the amount leaving the liver, corresponded to that part of newly formed PGFzu which was not degraded intrahepatically. After infusion of control serum, 36 _+ 5 pmol PGF2, . g- (Table 2 ) left the liver in a 10-min period between 30 and 40 min. The peak value was reached only 8 min after the onset of the infusion (Fig. 4A) . Activated serum caused a total outflow of 127 f 8 pmol PGF2, . g-between 30 and 40 min (Table 2) , the peak values already being reached within the first minute (Fig. 4B ). Since after a first stimulus the PGFza overflow returned towards basal levels only very slowly and had not reached prestimulation values at the start of the second stimulation, the overflow in the second period can be quantitated only by approximate extrapolation. Activated serum given as a second stimulus caused a further rapid increase in PGF2. output (Fig. 4A) , whereas control serum given as a second stimulus caused only a delay of the decay of PGFza overflow after activated serum as a first stimulus (Fig. 4B) . In the presence of the cyclooxygenase inhibitor indomethacin, no PGF2, was released from the liver either after control or after activated serum ( Table 2 ). Thus the stimulation of PGF2. formation by activated serum was fast, and that by the control serum was slow and smaller, independent of the order of stimulation.
DISCUSSION
Mechanism of action of complement-activated rat serum
-Complement-activated serum led to a much larger increase in glucose and lactate output, and reduction and redistribution of the flow, than the control serum (Fig. 1 ). The activation of serum was dependent on intact complement proteases, since it could be prevented by heat inactivation of the complement proteases prior to activation of the complement system (Table  l) , whereas the active agent was resistant to heat inactivation. It eluted on gel-filtration chromatography in the molecular mass range below 25 kDa and above 10 kDa (not shown). Thus most likely one or several of the small heat-stable proteins, that are formed during complement activation, account for the metabolic and hemodynamic effects of activated serum, rather than the large heat-sensitive protein complexes that are also formed during complement activation. Among the small proteins the anaphylatoxins C3a (molecular mass about 9000) and C5a (molecular mass about 12000) seem to be likely candidates. It has been previously shown that the human anaphylatoxin C3a was capable of increasing glucose and lactate output, and perfusion resistance in perfused rat liver, whereas human anaphylatoxin C5a was inactive [13] . Meanwhile it could be demonstrated that the lack of activity of the human anaphylatoxin C5a in rat liver was most likely due to species incompatibilities, since it was active in perfused guinea-pig liver (G. Piischel, unpublished results) .
The present results do not indicate whether C3a or C5a, or both, were active, yet they provide some indirect evidence. It appears more likely that C5a was the active serum component for the following reasons: (a) the fractions from the gel-chromatography separation of activated serum with a molecular mass below 10 kDa were inactive; (b) the carboxypeptidase inhibitor, D,L-mercaptomethyl-3-guanidinoethylthiopropanoic acid, did not enhance the effects of activated serum. This would have been expected if C3a had been the active agent, since C3a but not C5a loses its biological activity entirely after removal of the C-terminal arginine by serum carboxypeptidases [23 -251. Especially rat C5a-desArg is still very potent in contracting smooth muscle [24] .
The active components of the complement system do not seem to act directly on the hepatocytes, vascular or sinusoidal cells, but indirectly via mediation by non-parenchymal cells. This view is supported by the observation that eicosanoids which in the liver can only be formed in non-parenchymal cells [26] were involved in the action of complement-activated serum. The increase in glucose and lactate output, and perfusion resistance, could be abolished by the inhibitor of prostanoid synthesis, indomethacin, and by the TXAl antagonist, BM 13505 (Fig. 3) , which would indicate a major role for TXAz. Leukotrienes may also have a minor role, since a weak inhibition was also brought about by the lipoxygenase inhibitor NDGA and the LTC4/LTD4 antagonist CGP 35949 B (Fig. 2) . This inhibition, however, may have been unspecific. NDGA has been shown to partially inhibit cyclooxygenase in the concentration used [27, 281, CGP 35949 B inhibited the increase in glucose and lactate output, and perfusion resistance, brought about by the thromboxane analog U 46619 (0.1 pM) completely at 10 pM and partially at 1 pM concentrations (G. Piischel, unpublished results) . The thromboxane receptor antagonist BM 13505, in contrast, did not interfere with the action of LTD4 (M. Iwai and IS. Jungermann, unpublished results) . Thus, thromboxanes and other prostanoids, but probably not leukotrienes had a major role in the signal chain elicited by complement-activated serum.
Further evidence is provided by the observed overflow of TXB, and PGF2, into the hepatic vein (Fig. 4, Table 2 ). Thromboxane release alone could only account directly for the hemodynamic changes, but not for the metabolic changes, since TXA, does not alter glucose release in isolated hepatocytes in contrast to PGFzo, . The increase in glucose and lactate output, that was inhibited with the TXA, antagonist, could then be caused by a release of for example PGF,, from nonparenchymal cells in response to TXA,.
Function of the action of complement-activated serum
Apparently a systemic activation of the complement system can take notable influence on liver metabolism and hemodynamics. The liver was not able to protect itself against the circulating peptide components of the activated complement system. This could be indicated by the high sensitivity of the liver towards activated serum, which caused an increase in glucose and lactate output already in a dilution as high as 750-fold (Fig. 3) . Thus, it seems likely that concentrations of the active mediators that are sufficiently high can be formed pathophysiologically during septicaemia or endotoxaemia in patients or animals. A systemic activation of the complement system might therefore be a possible explanation for the increase of prostaglandin levels in livers of animals that had been injected with endotoxins intravenously [32] and possibly one of the mechanisms by which an increase in blood glucose is brought about in patients with severe sepsis.
